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ABSTRACT  1 
 2 
Chloroquine (CQ) has been a mainstay of antimalarial drug treatment for several 3 
decades. Additional therapeutic actions of CQ have been described, including 4 
some reports of fungal inhibition. Here, we investigated CQ action in fungi, 5 
including the yeast model Saccharomyces cerevisiae. The genome-wide yeast 6 
deletion strain collection was screened against CQ, revealing that bck1Δ and 7 
slt2Δ mutants of the cell wall integrity pathway are CQ hypersensitive. This 8 
phenotype was rescued with sorbitol, consistent with cell wall involvement. The 9 
cell wall targeting agent caffeine caused hypersensitivity to CQ, as did cell wall 10 
perturbation by sonication. The phenotypes were not caused by CQ-induced 11 
changes to cell wall components. Instead, CQ was accumulated to higher levels 12 
in cells with perturbed cell walls; CQ uptake was two- to three-fold greater in 13 
bck1Δ or slt2Δ mutants than in wild type yeast. CQ toxicity was synergistic with 14 
that of the major cell wall-targeting antifungal drug, caspofungin. The MIC for 15 
caspofungin against the yeast pathogen Candida albicans was decreased two-16 
fold by 250 µM CQ, and by up to five-fold at higher CQ concentrations. Similar 17 
effects were seen in C. glabrata and Aspergillus fumigatus. The results show that 18 
the cell wall is critical for CQ resistance in fungi, and suggest that combination 19 
treatments with cell wall-targeting drugs could have potential for antifungal 20 
treatment.  21 
  22 
INTRODUCTION 23 
 24 
Fungal infections continue to represent a serious challenge to human health, due partly to 25 
interventions or other diseases that may facilitate fungal proliferation. Patients with 26 
debilitating diseases such as HIV, organ transplant recipients, major burns patients and 27 
those treated with corticosteroids or other immunosuppressants are more susceptible to 28 
fungal infections. Among the most important opportunistic fungal pathogens are Candida 29 
spp., the fourth most common cause of nosocomial infection with a case rate of 72.8 per 30 
million people per year and a mortality rate close to 34% (1). Other fungal genera that are 31 
common pathogens include Aspergillus, Cryptococcus and Fusarium. Mortality rates are as 32 
high as 62% (2). Drugs used to treat fungal infections include the polyenes, azoles and 33 
echinocandins. However, with the limited number of antifungals available, newer 34 
treatments are required. Recently, combination treatments with antifungals have attracted 35 
considerable attention as a method of management, due to a paucity of newly emerging 36 
agents. An advantage of such combinations is that they reduce the likelihood of resistance 37 
(3).  38 
One factor that helps in the development of novel antifungal entities or in 39 
elucidating mode of action is that many fungal genome sequences are now available.  40 
Certain fungi are also highly amenable to laboratory manipulation. Thus, the yeast 41 
Saccharomyces cerevisiae has become broadly adopted as a eukaryotic cell model of 42 
choice. The yeast model has been applied to characterize the actions of antifungal drugs 43 
(4, 5) as well as a diverse range of other therapeutic compounds including antimalarial 44 
drugs (6, 7). Antimalarials are notoriously poorly characterized, with regard both to their 45 
modes of action against the malaria parasite and to the adverse reactions that many 46 
provoke in humans. A screen of the yeast deletion strain collection against the antimalarial 47 
drug quinine revealed a novel mode of quinine action (6). Mutants defective for 48 
biosynthesis of the amino acid tryptophan were quinine hypersensitive. Further 49 
experiments revealed that quinine competed with tryptophan for uptake via the Tat2p 50 
transporter leading to tryptophan starvation, suggesting a novel mechanism of quinine 51 
toxicity. Moreover, the power of the yeast model was exemplified by a recent extrapolation 52 
of these findings to malaria patients in hospitals (8). These clinical data indicated that 53 
quinine also competes with tryptophan in humans, and that dietary tryptophan may 54 
suppress adverse reactions of patients to quinine.   55 
The antimalarial drug chloroquine is chemically distinct from the structural 56 
relationship between quinine and tryptophan (6). Despite being an older drug, CQ is safe 57 
and inexpensive and remains a recommended antimalarial in areas affected by CQ-58 
sensitive malaria infections, particularly by Plasmodium vivax (9). The mode of CQ action 59 
has been attributed to binding of the drug to haem in the parasite food vacuole, resulting 60 
in decreased haem polymerization. Free haem is toxic to the parasite. CQ may also 61 
increase the pH of the parasite digestive vacuole or inhibit an endogenous function 62 
through binding to the PfCRT protein (10). In addition to this antimalarial activity, CQ has 63 
been shown to have anti-inflammatory properties and has been widely used in the 64 
treatment of arthritis (11). There have also been reports of CQ activity against fungal 65 
pathogens (12-15). The mechanism is thought to involve alkalinisation of the host 66 
environment of the fungi, with associated iron deprivation in some cases. CQ has also 67 
been shown to inhibit thiamine transport in yeast as well as human cells (16).  68 
 The objective at the outset of the study was to apply the yeast tool to gain new 69 
insights to chloroquine action. The cell wall integrity pathway genes SLT2 and BCK1 were 70 
characterised as key determinants of CQ resistance. With the aim of explaining this result, 71 
we showed that cell wall perturbation produces CQ hypersensitivity due to elevated CQ 72 
uptake. As the cell wall is the target of existing antifungal drugs, our final aim was to 73 
investigate the possibility of combining such drugs with CQ to give synergistic antifungal 74 
action.   75 
MATERIALS AND METHODS 76 
 77 
Yeast strains, deletion strain screen and growth assays. BY4743 was the strain 78 
background used in experiments involving Saccharomyces cerevisiae, except where stated 79 
otherwise. BY4743 and isogenic homozygous deletion strains were from Euroscarf 80 
(Frankfurt, Germany). Additional fungi used in this study were Candida albicans SC5314, 81 
C. glabrata BG2 and Aspergillus fumigatus AF293. S. cerevisiae YPH499 and the isogenic 82 
mutant YMS348s (chs1Δ,chs2Δ,chs3Δ) were kind gifts from Dr. Martin Schmidt, Des 83 
Moines University (17). Deletion strain screens were performed by replica inoculation of 84 
strains to YEPD broth in 96-well format, either supplemented or not with 2.9 mM 85 
chloroquine diphosphate (Sigma). The screen and calculation of growth ratios were 86 
performed as described previously (6). Briefly, growth ratios for each strain were 87 
calculated by dividing OD600 readings obtained under control conditions (minus CQ) by 88 
those for parallel CQ-supplemented incubations. Strains with a mean growth ratio of 89 
≥1.45 (n=2) from the initial screen were re-arrayed onto new 96-well plates and screened 90 
three further times in duplicate. Strains giving a median growth ratio across all screens 91 
≥1.45 were deemed to be CQ hypersensitive. For other growth experiments, overnight 92 
cultures in YEPD broth were diluted into fresh medium (10 ml in 50 ml flasks) and cultured 93 
with orbital shaking to OD600~2.0. For spotting assays, the cultures were serially diluted 94 
1:10 with phosphate buffered saline and spotted (5 µl) onto YEPD agar (18) supplemented 95 
as indicated with chloroquine, caffeine (Sigma), calcofluor white (Sigma) or sorbitol. Plates 96 
were observed after incubation at 30°C for 48 h.  97 
Epsilometer test (Etest) strips containing caspofungin were used to assay 98 
simultaneous treatments with chloroquine or related drugs and caspofungin. After sub-99 
culturing to YEPD broth and incubation for 3-4 hours to ~2 x 106 CFU ml-1, organisms were 100 
spread with a sterile cotton swab to cover the surface of RPMI-2G agar [RPMI 1640 101 
medium supplemented with 2% (w/v) glucose, 1.5% (w/v) agar and buffered with 0.165 102 
M MOPS (Sigma), adjusted to pH 7 with sodium hydroxide]. The agar was supplemented 103 
with amodiaquine, chloroquine, mefloquine, quinacrine or quinine, supplied at sub-104 
inhibitory concentrations. E-test strips containing caspofungin (BioMerieux) were placed 105 
aseptically onto the inoculated agar. Plates were incubated for 48 h at 30ºC (S. cerevisiae) 106 
or 37ºC before examination.  107 
 108 
Cell wall stress assay. Sonication was used to stress yeast cell walls, as described 109 
previously (19). Strains were cultured overnight in the absence or presence of CQ or 110 
caffeine. The cells were then sub-cultured to fresh medium supplemented as before and 111 
incubated for 3 h until OD600~1.0. Aliquots (1 ml) of cell suspension were transferred to 112 
microfuge tubes. Where specified, cells were washed twice with PBS to remove drugs 113 
before sonication. Samples were sonicated for 1 min at 70% power using a Sonicator 114 
(ColePalmer) equipped with a 3 mm-diameter probe. Samples (100 µl) were removed 115 
before and after sonication, diluted with PBS, and spread plated to YEPD agar. Percentage 116 
viability was determined from colony forming unit counts after incubation at 30ºC for 2 d, 117 
as described previously (20). All statistical analyses were performed with Statistical 118 
Package for the Social Sciences (SPSS) software, version 17. 119 
 120 
Determination of cell wall components. β-1,3-glucan was probed with aniline 121 
blue as described (21). Cells were cultured with or without CQ either overnight or for 3 h, 122 
until OD600=0.5–0.8, then diluted to 2.5 x 10
6 cells ml-1. Cells were washed with TE buffer 123 
(10 mM Tris, 1 mM EDTA, adjusted to pH 8 with HCl) and suspended in 250 µl of the same 124 
buffer. NaOH was added to a final concentration of 1 M before incubation at 80ºC for 30 125 
min. A 1.05 ml volume of aniline blue mixture [0.03% (w/v) aniline blue (Sigma), 0.18 M 126 
HCl, 0.49 M glycine/NaOH, pH 9.5] was added.  Samples were vortexed and incubated at 127 
50ºC for 30 min. After a further 30 min at room temperature, β-1,3-glucan was estimated 128 
by fluorescence spectrophotometry (Cary Eclipse Varian) at λex=400 nm, λem =460nm.  129 
The mannosylphosphate component of cell wall mannoprotein was determined with 130 
alcian blue staining as described previously (22). Cells were cultured with or without CQ 131 
either overnight or for 3 h, until OD600~1.0. Samples (5 ml) were washed twice with 2 ml 132 
0.02-M HCl and resuspended in 1 ml of 0.005% (w/v) alcian blue in 0.02 M HCl. The 133 
mixture was left to stand at room temperature for 10 min, then centrifuged for 3 min at 134 
18,000 g. Unbound alcian blue was determined from OD600 of the supernatant, with 135 
reference to a standard curve prepared with alcian blue solutions ranging from 0 to 0.05% 136 
(w/v) in 0.02 M HCl. The amount of alcian blue bound to cells was then calculated by 137 
subtracting the amount of unbound dye from the starting amount of 50 µg alcian blue. 138 
The chitin content of cell walls was probed with calcoflour white (23). Cells were 139 
cultured with or without CQ either overnight or for 3 h, then adjusted to 1 x 106 CFU ml-1, 140 
washed twice with PBS and stained with 1.1 µM calcofluor white for 30 min. Stained cells 141 
were washed and resuspended in 1 ml PBS. Calcofluor white fluorescence was quantified 142 
with a Becton Dickinson LSR Flow II flow cytometer, equipped with a 365nm laser. 143 
Calcofluor white was detected with a 440/40BP emission filter.  144 
 145 
Chloroquine uptake. Chloroquine uptake by cells was estimated using a 146 
fluorescently-labelled chloroquine molecule, LynxTag-CQ™ Green (BioLynx Technologies). 147 
Aliquots (100 µl) of cells grown to OD600~2.0 in YEPD broth were transferred to microfuge 148 
tubes. Chloroquine was added together with 2 µl of 1-mM LynxTag-CQ™ and, where 149 
specified, caffeine. Cells were incubated in the dark with shaking at 30ºC. Samples (10 µl) 150 
were removed at intervals and cells washed and resuspended in a 1:100 dilution of PBS. 151 
Fluorescence from cellular LynxTag-CQ™ Green was measured with a Becton Dickinson 152 
FACSCanto flow cytometer, with excitation at 488 nm and emission detected through a 153 
505LP, 530/30BP filter. A 10 µl sample was also washed and examined with a 100X oil 154 
immersion lens and appropriate filters to confirm the presence of CQ within yeast cells.155 
RESULTS 156 
 157 
Deletion strains with altered chloroquine resistance. The yeast homozygous diploid 158 
deletant collection was screened to identify genes that are important for CQ resistance. 159 
Preliminary experiments showed that 2.9 mM CQ was just sufficient to exert a mild 160 
(∼10%) slowing on wild type growth, and this concentration was selected for screening. A 161 
total of 97 CQ-sensitive strains (growth ratio ≥1.45) were identified from the genome-162 
wide screen, and 23 of these phenotypes were subsequently confirmed in specific tests of 163 
the 97 putative strains (see Table S1 in the supplemental material). The 23 deleted genes 164 
of the sensitive strains were grouped into functional categories (24) and the resultant 165 
distributions analyzed for significant differences compared with genome-wide distributions 166 
for S. cerevisiae. ‘Stress Response’ was the most highly over-represented functional 167 
category in the annotations of genes in the CQ sensitive dataset, owing to the sensitivity 168 
of deletion strains including sat4Δ/sat4Δ, slt2Δ/slt2Δ and bck1Δ/bck1Δ (Table 1). The 169 
evident requirement for SLT2 and BCK1 in normal quinine resistance yielded additional 170 
over-represented categories, including MAPKKK cascade and directional cell growth.  171 
 172 
The CQ sensitivity of cell-wall integrity pathway mutants is bck1Δ-, slt2Δ- 173 
and drug-specific. Bck1p and Slt2p have key roles in the cell wall integrity pathway (25-174 
27). We conducted specific CQ-resistance tests with other mutants of the pathway. These 175 
were not detected in the above screen (Table 1) but the screen criteria were stringent to 176 
avoid false positives (6). Whereas the bck1Δ /bck1Δ and slt2Δ/slt2Δ mutants showed 177 
marked growth defects versus wild type in the presence of CQ (Fig. 1), any effects in other 178 
Slt2 pathway mutants were slight (see Fig. S1A in the supplemental material). [Note that 179 
particularly high CQ concentrations (>10 mM) were required in certain of these 180 
experiments to overcome the CQ resistance of wild type S. cerevisiae; the relevant MICs 181 
were ~20, 1.5 and 1.5 mM CQ for the wild type, bck1Δ/bck1Δ and slt2Δ/slt2Δ strains, 182 
respectively]. Similarly, deletion strains defective for cell surface sensors that signal to the 183 
Slt2 pathway were not markedly CQ-sensitive (see Fig. S1B in the supplemental material). 184 
There is some redundancy within the cell wall integrity pathway (25, 27), and the results 185 
indicate that it is a non-compensatable defect in the pathway (brought about only by BCK1 186 
or SLT2 deletion) that is required to elicit the CQ sensitivity phenotype.  187 
 The effect of BCK1 or SLT2 deletion on drug sensitivity was tested with other 188 
quinoline-containing antimalarials; quinine, mefloquine, amodiaquine and quinacrine. 189 
Unlike CQ, none of these other drugs revealed a marked hypersensitivity phenotype of the 190 
mutants versus wild type (Fig. 1). The mutants exhibited a very slight sensitivity to 191 
quinacrine. The results highlight the CQ-specificity of the phenotypes.  192 
  193 
Cell wall damage and chloroquine resistance. Deletion of BCK1 or SLT2 in S. 194 
cerevisiae, as well as in pathogens like Candida spp., has been reported to yield sensitivity 195 
to cell wall damaging agents, such as caffeine and calcofluor white (CW) (28, 29). To 196 
corroborate an involvement of cell wall integrity in CQ action, we tested the effects of 197 
caffeine or CW on CQ resistance. The bck1Δ /bck1Δ and slt2Δ/slt2Δ mutants were 198 
confirmed to be caffeine and CW hypersensitive (Fig. 2A). Consistent with cell wall damage 199 
this sensitivity was rescued with 1 M sorbitol, and this was also the case for CQ (Fig. 2A). 200 
CQ was supplied in combination with CW or caffeine at concentrations that were just sub-201 
inhibitory to the relevant yeast strains when each drug was supplied alone. CW did not 202 
cause hypersensitivity to CQ (Fig. 2B). However, a combination of CQ and caffeine gave 203 
markedly greater growth inhibition than the individual effects of the two drugs. This effect 204 
was apparent in wild type, bck1Δ/bck1Δ and slt2Δ/slt2Δ strains. This indication of some 205 
synergy in the effects of CQ and caffeine suggested that these drugs may have different 206 
molecular targets, but their actions involve a common metabolic product or cell structure.  207 
 To substantiate that CQ action is related to cell wall integrity, cells were sonicated 208 
during CQ exposure. Sonication physically weakens the yeast cell wall and makes it more 209 
susceptible to the actions of chemical cell wall stressors (19). Wild type cells were cultured 210 
with different sub-inhibitory concentrations of caffeine or CQ, then viability was 211 
determined before and after sonication for 1 min in the presence of caffeine or CQ. In 212 
controls where drugs were absent, the sonication treatment had negligible effect on 213 
viability (Fig. 3). However, in the presence of 4 mM caffeine or CQ, viability was decreased 214 
~80% by sonication. This was consistent with CQ action being related to cell wall integrity.  215 
 216 
CQ toxicity is not mediated by effects on cell wall composition. We 217 
considered two hypotheses to explain the above results: 1. The mode of CQ action against 218 
yeast involves targeting of the cell wall, similar to CW and caffeine. 2. Cell wall integrity is 219 
important for CQ resistance, possibly by preventing intracellular access of the drug. To 220 
give clues to any specific cell wall components that may be affected by CQ (hypothesis 221 
#1), first we conducted specific CQ resistance assays with 70 mutants defective for 222 
biosynthesis of different cell wall components, including β-1,3 glucan, β-1,6 glucan, 223 
mannoprotein and chitin. These mutants were not detected as CQ-sensitive in the screen 224 
(see Table S1 in the supplemental material), nor did they prove to be CQ sensitive in our 225 
specific assays (data not shown). This suggested that CQ does not target a particular cell 226 
wall component. To corroborate this, we assayed each of the major cell wall components 227 
of S. cerevisiae, exposed or not to CQ. The outcomes described below did not differ 228 
whether cells were incubated for 3 h or overnight in the presence of CQ before cell wall 229 
analysis. Aniline blue staining was used to indicate β-1,3 glucan content (21), which did 230 
not differ significantly between CQ-exposed and non-exposed cells (see Fig. S2A in the 231 
supplemental material). Similar results were obtained for the mannosylphosphate 232 
component of cell wall mannoprotein (see Fig. S2B in the supplemental material), 233 
according to alcian blue staining (22). However, using a sub-inhibitory concentration of 1.1 234 
µM CW in order to stain chitin (23, 30) we noted a >1.5-fold increase in the apparent 235 
chitin composition of the cell walls of CQ treated cells (Fig. 4A) (p≤0.0002 at all CQ 236 
concentrations versus the CQ-free control). To test whether increased chitin content may 237 
be a cause of CQ toxicity, a chitin-defective triple chitin synthase mutant YMS348s 238 
(chs1Δ,chs2Δ,chs3Δ) was examined for CQ resistance. First it was confirmed that the 239 
mutant was resistant to normally-inhibitory concentrations of CW (Fig. 4B), consistent with 240 
a mode of CW action involving binding to nascent chitin fibrils (31, 32). In contrast, the 241 
YMS348s mutant exhibited similar CQ resistance as the isogenic wild type, indicating that 242 
(increased) chitin is not an important mode of CQ action (Fig. 4B). We confirmed that 243 
there was no CQ-dependent increase in chitin content in the YMS348s mutant. 244 
 245 
Cell wall perturbation facilitates CQ uptake into yeast cells. As the above 246 
data did not support the hypothesis that CQ causes cell wall damage, we considered the 247 
alternative hypothesis (#2) that cell wall integrity is required for normal CQ resistance. 248 
Therefore, we performed sonication assays similar to those shown in Fig. 3 but where the 249 
drug was removed just prior to sonication. We reasoned that if cell wall damage caused by 250 
(prior) CQ exposure was the reason for sonication sensitivity (Fig. 3), then cells should still 251 
exhibit such sensitivity for some time after removing CQ. In contrast, the continued 252 
presence of CQ would be required for sonication sensitivity if the relevant effect was to 253 
enable CQ entry to the cell. In the case of caffeine as a positive control, viability was 254 
decreased by ≥80% due to sonication whether 4 mM caffeine was retained (Fig. 3) or 255 
removed just prior to sonication (Fig. 5A) (sonication without any caffeine treatment had 256 
negligible effect on viability). In contrast, cells were relatively resistant to sonication after 257 
growth in up to 10 mM CQ when the drug was removed before sonication (Fig. 5B), 258 
whereas 4 mM CQ during sonication produces a ~80% loss of viability (Fig. 3). These 259 
outcomes for CQ were consistent with the hypothesis that normal cell wall integrity helps 260 
to prevent CQ entry and its resultant toxicity in cells. To test that directly, uptake of the 261 
drug was examined with a fluorescent probe approach (33). LynxTag-CQ uptake was 262 
approximately two-fold and three-fold higher in the bck1Δ/bck1Δ and slt2Δ/slt2Δ mutants, 263 
respectively, than in wild type S. cerevisiae (Fig. 6A). This was in keeping with these 264 
mutants’ CQ sensitivities. Similarly, other treatments used above to perturb the cell wall 265 
(caffeine treatment and sonication) and which sensitized cells to CQ were also associated 266 
with increased LynxTag-CQ uptake (Fig. 6B,C). The results indicated that CQ toxicity is 267 
greater in cell wall-perturbed cells due to increased CQ uptake. 268 
 269 
Synergistic activity of caspofungin and chloroquine. The dependency of 270 
chloroquine resistance on yeast cell wall integrity suggested the possibility that 271 
chloroquine could have synergistic therapeutic action with a cell wall-targeting antifungal 272 
drug. The echinocandin drug caspofungin (CSP) and CQ were examined for synergistic 273 
effects on pathogenic fungi, using CSP Etest strips as applied clinically and following the 274 
guidelines for synergy determination (34). In Candida albicans, there was evidence for 275 
marked synergy with sub-inhibitory concentrations of CQ (Fig. 7). For example, 276 
simultaneous exposure to 2 mM CQ decreased the minimal inhibitory concentration (MIC) 277 
for CSP by approximately three fold. In contrast, only additive effects were observed with 278 
sub-inhibitory concentrations of other quinolone-containing drugs (Table 2). The above 279 
analyses also inferred a marked drop in the MIC for CQ in the presence of CSP, where ~20 280 
mM CQ was required for growth inhibition in the absence of CSP but only ∼0.125 mM CQ 281 
inhibited growth at 0.25 μg ml-1 CSP. CQ and CSP also exhibited synergistic action against 282 
C. glabrata. Although the effect was less marked than in the Candida spp., the MIC for 283 
CSP was decreased by the presence of CQ also in the CQ-sensitive filamentous pathogen 284 
Aspergillus fumigatus. The data indicate that the antifungal action of CSP is increased by 285 
the presence of CQ and vice versa. The fact that these effects of CQ were evident among 286 
several fungi with differing cell wall compositions (35) was in keeping with the observation 287 
that overall integrity of the cell wall rather than particular cell wall components determines 288 
CQ resistance (see “CQ toxicity is not mediated by effects on cell wall composition”). 289 
290 
DISCUSSION 291 
 292 
S. cerevisiae was successfully used as a tool in this study to elucidate how fungi with 293 
perturbed cell walls are hyper-sensitized to chloroquine. The fungal cell wall has been a 294 
long-standing target for development of other antifungal drugs. The echinocandin 295 
antifungals target one of the main cell wall components, β-1,3 glucan, and are used to 296 
treat invasive fungal infections by Candida and Aspergillus spp. (36, 37). Here, the CQ-297 
hypersensitivity of the bck1Δ/bck1Δ and slt2Δ/slt2Δ yeast deletion mutants highlighted a 298 
role for the mitogen-activated protein kinase (MAPK) cell wall integrity pathway (25-27). 299 
This was specific to CQ resistance, versus other closely related quinoline-containing 300 
antimalarials. One structural difference between the drugs that may be pertinent here is 301 
the occurrence of an aryl side chain in quinine, amodiaquine and mefloquine, whereas CQ 302 
and quinacrine have an alkyl side chain (38). As quinacrine was the only drug tested other 303 
than CQ where there was a suggestion of sensitivity in the bck1Δ/bck1Δ and slt2Δ/slt2Δ 304 
mutants, the alkyl side chain may be one structural feature that helps determine this 305 
phenotype. A key difference is that quinacrine has three fused aromatic rings, whereas CQ 306 
has two rings. 307 
Agents that target a component of the fungal cell wall typically cause altered levels 308 
of that component. The content of other cell wall components is commonly modified in 309 
compensation, to help sustain cell wall strength and integrity (39). The fact that mutants 310 
for cell wall components were not CQ-hypersensitive was consistent with the cell wall not 311 
being the primary target of CQ action. There were increases in chitin content of CQ 312 
exposed cells, but chitin was not a target of CQ action as chitin synthase defective cells 313 
were not affected for CQ resistance. This contrasted with calcofluor white which interferes 314 
with chitin formation as its mode of action, and causes increased chitin synthase activity 315 
(31, 32, 40, 41). The increased chitin content seen with CQ appeared to be an incidental 316 
effect, consistent with the fact that the cell wall acts to help block CQ uptake rather than 317 
be targeted by CQ action.  318 
Little is known about the uptake of quinolone-containing drugs into yeast cells. 319 
However, a mode of antifungal CQ action based on alkalinisation of the host environment 320 
and iron deprivation has been proposed (12, 14, 15). Pathogens like C. albicans 321 
themselves can actively alkalinise their environments (42), an action that could 322 
exacerbate CQ action. Related mechanisms of CQ action are known in Plasmodium spp. 323 
(10). Recently, CQ was shown to inhibit thiamine transporters in both yeast and human 324 
cells (16). Our study indicates that the fungal cell wall acts as a barrier to help preclude 325 
the toxic action(s) of CQ and, therefore, that the potential of CQ as an antifungal agent 326 
(12-15) is enhanced considerably by cell wall perturbation. 327 
The potential value of drug combinations for the management of fungal infections is 328 
well documented (3). For example, cell wall perturbing agents can be used in conjunction 329 
with antifungals such as polyenes and triazoles that target the cell membrane, a strategy 330 
that has proven beneficial in critically ill patients (43). Drug combinations may reduce the 331 
risk of resistance, adverse effects and improve treatment duration. The use of one 332 
antifungal to increase penetration of another was exploited here with CQ and the cell wall-333 
targeting echinocandin drug caspofungin (CSP). CSP is used to treat serious fungal 334 
infections such as those caused by Candida spp. (where Slt2p can determine CSP 335 
tolerance, as in S. cerevisiae) (44, 45), and has been used alongside other antifungals 336 
such as amphotericin and fluconazole (36, 37). CSP acts by targeting the enzyme complex 337 
β-1,3 glucan synthase required for β-1,3 glucan synthesis. In the present study, sub-338 
inhibitory concentrations of CQ and caspofungin exhibited synergistic activity in vitro. This 339 
was observed in pathogenic fungi (C. albicans, C. glabrata and A. fumigatus) as well as S. 340 
cerevisiae. The lowest concentration at which a decrease in the MIC for caspofungin was 341 
evident in vitro was 125 µM CQ. This concentration is higher than is typically encountered 342 
in the clinical setting. In vivo concentrations in the plasma of patients treated with CQ are 343 
reported to be <5.9 µM (46). Furthermore, concentrations as low as 32 µM CQ are known 344 
to cause growth inhibition in human cell lines (47). However, whereas the concentrations 345 
used in this study were appropriate in vitro, a mode of antifungal CQ action that relies on 346 
iron deprivation due to external alkalinisation (12, 14, 15) could be expected to be 347 
markedly exacerbated in vivo. Thus, fungal pathogens would be likely to be more 348 
susceptible to caspofungin-dependent CQ uptake during in vivo infection. Accordingly, the 349 
synergistic activities of CQ and caspofungin could have the potential for clinical application. 350 
A particular advantage of this possibility is that inclusion of inexpensive CQ could mean 351 
that less of the more-expensive echinocandin drug is needed for treatment. In addition, 352 
thanks to the extensive treatment of malaria patients with the drug over the last several 353 
decades, CQ is known to be relatively safe and is very well characterized for other 354 
indications. The findings could prove especially relevant to malaria patients with serious 355 
fungal infections (48, 49).  356 
 357 
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 517 
  518 
TABLE 1 Over-representation of specific functional categories in the 
annotations of genes from the chloroquine-sensitive dataset  
Functional categorya,b P valuec  Genes 
Stress response 1.51 x10-3 YBR016W, SAT4, SLT2, 
BCK1 
Modification by phosphorylation, 
dephosphorylation, 
autophosphorylation 
 
2.51 x10-3 
 
SAT4, SLT2, BCK1, PTC5
MAPKKK cascade 3.22 x10-3 SLT2, BCK1 
Directional cell growth 
(morphogenesis)  
Vacuole or lysosome 
4.51 x10-3 
8.41 x10-3 
SLT2, BCK1 
VPS41, TLG2 
aThe dataset comprises the defective gene function of each deletion strain that 
scored chloroquine sensitive. 
bAll functional categories scoring P≤0.01 are shown  
cAccording to http://funspec.med.utoronto.ca/  
 519 
  520 
TABLE 2 Antifungal Etest assays of caspofungin and chloroquine drug combinations 521 
 522 
Organism 
 
Drug 
 
Concentration 
(mM) 
Caspofungin MICa 
(µg ml-1) 
Effectb 
 
C. albicans SC5314 None 0 0.38 N/A 
 CQc 0.125  0.25 Additive 
  0.25 0.19 Additive 
2 0.125 Synergy 
12 0.047 Synergy 
AQ 0.06 0.38 Additive 
0.3 0.38 Additive 
QN 0.4 0.38 Additive 
2.0 0.38 Additive 
MQ 0.01 0.38 Additive 
0.05 0.38 Additive 
QCR 0.05 0.25 Additive 
0.25 0.125 Synergy 
C. glabrata BG2 None 0 0.5 N/A 
CQ 0.4 0.19 Synergy 
2.0 0.023 Synergy 
A. fumigatus AF293 None 0 0.19 N/A 
CQ 0.05 0.19 Additive 
  0.25 0.094 Additive 
S. cerevisiae BY4743 None 0 1.5 N/A 
 CQ 3  0.25 Synergy 
  15  0.064 Synergy 
   523 
aMIC, Minimum inhibitory concentration. Results from triplicate determinations were 524 
identical, so errors are not shown. 525 
bFor definitions of synergy and additivity see the legend to Figure 7.  526 
cWhen supplied alone, CQ was non-inhibitory at all the indicated concentrations. The MICs 527 
for CQ were: C. albicans, 15 mM; C.glabrata, 4 mM; A. fumigatus, 0.5 mM; S. cerevisiae, 528 
20 mM.  529 
 530 
  531 
LEGENDS TO FIGURES 532 
 533 
 534 
FIG 1 Chloroquine sensitivity of strains defective for BCK1 or SLT2. Exponential phase 535 
cultures of S. cerevisiae BY4743, and isogenic strains bck1Δ/bck1Δ and slt2Δ/slt2Δ were 536 
serially diluted and spotted to agar supplemented or not with drugs (CQ, chloroquine; AQ, 537 
amodiaquine; MQ, mefloquine; QCR, quinacrine; QN, quinine) at the indicated 538 
concentrations. Images were captured after incubation for 48 h at 30°C. 539 
 540 
FIG 2 Rescue of chloroquine sensitivity by sorbitol, and synergistic action with caffeine. (A) 541 
Exponential phase cultures of S. cerevisiae BY4743 (WT), and isogenic strains 542 
bck1Δ/bck1Δ and slt2Δ/slt2Δ were serially diluted and spotted to agar supplemented or 543 
not with CQ, caffeine or calcofluor white (CW) at the indicated concentrations and in the 544 
absence (left panels) or presence (right) of 1 M sorbitol. (B) Strains were spotted to agar 545 
supplemented with the agents at concentrations that were just sub-inhibitory to the 546 
relevant strains(s) when supplied singly. The same concentrations were used in 547 
combinations of the agents. All images were captured after incubation for 48 h at 30°C. 548 
 549 
FIG 3 Sonication sensitizes cells to chloroquine. Overnight cultures of S. cerevisiae BY4743 550 
supplemented with the indicated concentrations of caffeine or chloroquine were sonicated 551 
for 1 min. Percentage viability was calculated from colony forming unit counts determined 552 
after sonication with reference to corresponding counts before sonication (without 553 
sonication, neither caffeine nor chloroquine affected viability at the indicated 554 
concentrations; sonication alone did not significantly affect viability). Mean ±SEM values 555 
are shown from three independent determinations. 556 
  557 
FIG 4 Chloroquine-induced increases in cell wall chitin are not a cause of chloroquine 558 
toxicity. (A) Cultures of S. cerevisiae BY4743 were incubated for 3 h with the indicated 559 
concentrations of chloroquine then probed for chitin content with 1.1 µM CW (this 560 
concentration is non-inhibitory to BY4743). Mean values ±SEM are shown from three 561 
independent determinations. (B) Exponential phase cultures of S. cerevisiae YPH499 (wild 562 
type) and a chitin synthase-defective derivative strain YMS348s (chs1Δ,chs2Δ,chs3Δ) 563 
were serially diluted and spotted to agar supplemented or not with 22 µM CW or 25 mM 564 
CQ. Images were captured after incubation for 48 h at 30°C. 565 
 566 
FIG 5 Sonication hypersensitivity requires the presence of chloroquine during sonication. 567 
Overnight cultures of S. cerevisiae BY4743 supplemented with the indicated 568 
concentrations of caffeine or chloroquine were washed to remove drug then sonicated for 569 
1 min. Percentage viability was calculated from colony forming unit counts determined 570 
after sonication with reference to corresponding counts before sonication (without 571 
sonication, neither caffeine nor chloroquine affected viability at the indicated 572 
concentrations; sonication without prior drug exposure did not significantly affect 573 
viability). Mean values ±SEM are shown from three independent determinations. 574 
 575 
FIG 6 Cells with perturbed cell walls accumulate larger amounts of chloroquine. (A) 576 
Exponential phase cultures of S. cerevisiae BY4743 () and isogenic strains bck1Δ/bck1Δ 577 
() and slt2Δ/slt2Δ () were incubated in the presence of 0.4 mM chloroquine spiked with 578 
20 µM LynxTag-CQ™. Cellular LynxTag-CQ™ was determined at intervals with flow 579 
cytometry. (B) LynxTag-CQ™ uptake was determined in BY4743 cells after incubation for 580 
3 h with 1 mM CQ, or 1 mM CQ plus 1 mM caffeine. C. LynxTag-CQ™ uptake was 581 
determined in BY4743 cells during incubation with 4 mM CQ, before or after sonication for 582 
1 min. All values are means ±SEM from three independent determinations. 583 
 584 
FIG 7 Synergistic action of caspofungin and chloroquine against Candida albicans. (A) C.  585 
albicans SC5314 was spread plated to RPMI-2G agar and overlaid with an Etest 586 
caspofungin strip. Images of growth were captured after 48 h incubation at 37ºC. (B) The 587 
MIC for caspofungin was determined from Etest analysis (A) in agar supplemented with 588 
different sub-inhibitory concentrations of chloroquine. Results from triplicate 589 
determinations were identical, so error bars are not shown. Synergy was defined as a 590 
decrease of ≥3 dilutions according to Etest in the combination MIC compared to control. 591 
Additivity (or indifference) was defined as a decrease of <3 (34, 50). When supplied alone, 592 
CQ was non-inhibitory at all the indicated concentrations. 593 
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